[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009

October 2009 | 78 pages | ID: CC6F739B808EN
FirstWord

US$ 995.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Every year, the numbers grow exponentially: 10.9 million new cancer diagnoses worldwide, 6.7 million cancer deaths annually.

But as the number of cases expand, so, too, does the number of five-year survivors—and the amount of groundbreaking oncology research, new drugs developed and biotechnology innovations. From the impact of Avastin in combination with chemotherapy to the hopeful results for HER2-positive gastric patients treated with Herceptin, the world of oncology is expanding its knowledge base at a rapid pace. These and other critical international developments were recently discussed at the ECCO 15 – ESMO 34 Congress, held September 20 to 24.

FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 takes you behind the scenes at the conference, where 15,000 cancer researchers, key opinion leaders, physicians and pharmaceutical companies gathered in Berlin, Germany to hear 2,000 presentations covering the entire spectrum of cancer, from research to prevention and through key fields, including breast colorectal, breast, lung, head-and-neck and gastrointestinal cancer.

Key insights from the conference

FirstWord’s wide-ranging report succinctly summarizes the most important news, results and outcomes from one of Europe’s largest and most important oncology congresses into easy-to-access, concise segments. The conference dossier provides accurate reviews of major clinical trial results, conveniently ordered according to specific fields of oncology. And unlike any other report, FirstWord’s Conference Intelligence Dossier: ECCO 15 - ESMO 34 Congress, 2009 offers a unique analysis of the use of social media at scientific congresses, the lessons and successes – and how the pharmaceutical industry can best employ it to capture issues and the attention of health care professionals.

The report’s overview of the conference offers:
  • The key final and interim results for a number of important clinical trials grouped by field, including:
    • Roche’s Xeloxa study
    • Phase III results for Amgen Inc’s Vectibix plus chemotherapy treatment study
    • Initial outcomes for the BOXER/Avastin trial
    • An analysis of the ToGA/Herceptin outcomes for HER2-positive gastric patients
    • Analysis of the ZODIAC/Vandetanib trial
    • Results of the TEAM study comparing Tamoxifen to Exemestane
    • Conclusions from the Sanofi-aventis TAX324 study
  • Brief outlines of all relevant drug posters
  • Unique quantitative and qualitative analysis of the conference’s use of social media such as Twitter, shared content, professional networking and Facebook, as well an analysis of how the pharmaceutical industry can harness the new technology to access health care professionals, improve quality of engagement and build reputations in communities of interest
  • Additional information including key presenter biographies
EXECUTIVE SUMMARY

SOCIAL MEDIA ACTIVITY AT THE CONGRESS

CLINICAL TRIAL UPDATES

Gastrointestinal (GI) Malignancies
  Non-colorectal GI Cancer
    The UK ABC-02 trial
    Sunitinib (SU) versus placebo for treatment of progressive, well-differentiated pancreatic islet cell tumours
    Final results of Phase III study of axitinib (AG-013736; A) plus gemcitabine in pancreatic cancer
    ToGA trial
    Posters on non Colorectal
  Colorectal Cancer
    AGITG MAX trial –Final results
    The FIRIS study
    '181' trial- panitumumab with FOLFIRI versus FOLFIRI
    XELOXA STUDY
    PRIME trial-(Panitumumab Randomised trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy)
    COIN Study
    Posters on Colorectal cancer
Lung Cancer
  ZODIAC trial
  WJTOG 3405
  Gefitinib response in patients with EGFR mutation
  ZEST STUDY
  Final NATCH data
  SATURN study
  NEJ002 study: A randomised Phase III study comparing 4 gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small-cell lung cancer (NSCLC) with sensitive EGFR mutations
  Posters on lung cancer
Breast Cancer
  Breast Cancer - Early Disease
    IES study: Intergroup Exemestane Study
    ZORO study: Zoladex Rescue of Ovarian Function
    TEAM study: Tamoxifen Exemestane Adjuvant Multinational study
    ABCSG-24 study- Austrian Breast Cancer and Colorectal Cancer Study Group
  Breast Cancer - Advanced Disease
    MONICa: Mono efficacy of Capecitabine
    CIRG/TORI 010: first analysis of a randomised Phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer
    A 3-arm randomised Phase II study of oral vinorelbine (NVBo) plus capecitabine (X) versus NVBo and X in sequential versus docetaxel (D) plus X in patients with metastatic breast cancer (MBC) previously treated with anthracyclines
  Breast Cancer - Bisphosphonates
    Denosumab versus zoledronic acid
    Posters on breast cancer
Prostate cancer
  Overall survival in men with and without prevalent vertebral fracture receiving androgen deprivation therapy for non-metastatic prostate cancer
Head and Neck
  Results of TAX324
Ovarian Cancer
  MORAb-003
  Posters on ovarian cancer
Renal Cancer

SOCIAL MEDIA AT ECCO 15 - ESMO 34

Quantitative and qualitative activity analyses
  Twitter: status updating
  Facebook: social networking
  Shared content: video, image, and document services
  Professional networking
Social media spotlights: activity analysis at ECCO 15 - ESMO 34 by constituency
  Key opinion leaders
  Pharmaceutical industry
  Professional societies
Trending topics within social media at ECCO 15 - ESMO 34
  Issues: debate, interaction, conversation and comment
  Events: planned, spontaneous, formal and casual
Beyond the conference centre
  Blog coverage of ECCO 15 - ESMO 34
Overview
  Levels of social media activity at ECCO 15 - ESMO 34 and beyond
  Counterpoints: social media representations of ECCO 15 - ESMO 34

BIOGRAPHIES OF KEY PRESENTERS

APPENDIX

INDEX

SOURCES


More Publications